Pfizer (NYSE:PFE) and Starbucks (NASDAQ:SBUX) are both trying to convince investors that difficult stretches are giving way to more durable growth. The latest numbers give each company something to point to. Starbucks has returned to transaction growth and expanding margins, while Pfizer raised its 2026 revenue outlook after another quarter of strong growth from newer and acquired products.
For retirees and income-focused investors, however, this is not simply a contest over which stock could rise faster. The more useful question is which business offers the better combination of current income, financial progress, and manageable risk while its turnaround plays out. On those terms, Pfizer and Starbucks look very different.
Both Turnarounds Are Showing Real Progress
Starbucks has the more visible operating comeback. Global comparable-store sales rose 7.9% in fiscal Q3 2026, including a 4.2% increase in transactions, while non-GAAP operating margin expanded 430 basis points from a year earlier to 14.4%. Non-GAAP earnings reached $0.85 per share, up 70%, and management raised full-year guidance to $2.55 to $2.65 in non-GAAP EPS. Those numbers suggest Brian Niccol’s “Back to Starbucks” strategy is moving beyond promises and beginning to show up in both customer traffic and profitability.
Pfizer’s recovery is less dramatic, but its newer products continue to carry more of the load. First-quarter revenue reached $14.45 billion, with revenue from launched and acquired products rising 22% operationally. In Q2, that group grew another 18% operationally. Total Q2 revenue was $15.0 billion, and Pfizer raised the midpoint of its 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion while maintaining adjusted EPS guidance of $2.80 to $3.00.
The Risks Behind Each Recovery Are Very Different
Starbucks still has to prove that stronger traffic can translate into lasting profit improvement. The company has invested heavily in labor, store operations, and its broader turnaround, and its Q3 balance sheet showed a shareholders’ deficit of about $7.67 billion. A negative book-equity balance does not by itself mean a company is financially distressed, but it is one more reason retirement investors should look beyond improving same-store sales. The encouraging sign is that margins are now moving in the right direction alongside transactions.
Pfizer faces a different challenge: replacing revenue as older blockbuster drugs lose exclusivity. That makes its pipeline and newer commercial products unusually important. Strong growth from products such as Padcev, Nurtec, and Lorbrena helps, but pharmaceutical development remains unpredictable and patent expirations can create sizable revenue holes. Pfizer therefore offers more current income than Starbucks, but shareholders are accepting real drug-development, competition, and patent-cliff risk while they collect it.
Pfizer Pays Significantly More Income While Investors Wait
This is where the comparison becomes more relevant for retirees. Pfizer currently pays a quarterly dividend of $0.43 per share, equivalent to $1.72 annually if that rate continues. Starbucks pays $0.62 quarterly, or $2.48 annualized, but its higher share price means its dividend yield is considerably lower. Exact yields change with the stock price, so investors should check the current figure before buying rather than relying on a percentage that may quickly become outdated.
Starbucks deserves credit for consistency. Its August 2026 payment marked 65 consecutive quarters of dividends. Pfizer also continues to make the dividend a central part of its capital-allocation plan. Neither payment is guaranteed, however, and dividend income should never be treated as a substitute for adequate cash reserves. For someone already withdrawing from a portfolio, Pfizer’s larger income stream may reduce the amount of stock that must be sold to generate cash, but only if the investment otherwise fits the portfolio’s risk and diversification needs.
For Retirement Income, Pfizer Has the Edge Today
Starbucks may ultimately produce the stronger growth story. Transactions are rising, margins have improved, and management has raised its fiscal 2026 outlook. Investors with a longer time horizon who care more about capital appreciation than immediate income could reasonably prefer that setup. But its turnaround still depends heavily on sustained consumer demand and continued improvement in store economics, while the dividend contributes a relatively modest amount of current income.
Pfizer looks more compelling for an investor whose priority is income today. Its 2026 revenue outlook has improved, newer products are growing quickly, and the quarterly dividend provides substantially more income relative to the share price. That does not make Pfizer the safer stock or guarantee better returns. Patent expirations, pipeline setbacks, pricing pressure, and competition remain meaningful risks. But between these two turnarounds, Pfizer currently offers the more natural fit for a retirement portfolio built partly around dividend income.
